Supporting this concept, the expressions of suggested miR-22 targets that were previously characterized in vitro in cancer cells were not affected by miR-22 deletion in hepatic mouse tissues, regardless of whether they were previously identified as tumor suppressors, e.g., PTEN or ERα, or as oncogenes, e.g., SIRT1, EZR, CD147, or SP1 [27,32,34,35,36,37,73] (Figure S9). The gene discussed is BSG; the disease is neoplasm.